Rapid RV/LV vs ElucidVivo A.3
AI Verdict
Choose Rapid RV/LV if…
Choose Rapid RV/LV if your primary need is a rapid, automated assessment of pulmonary embolism severity in acute settings. This tool is ideal for emergency departments and critical care units requiring immediate RV/LV ratio calculations from CTPA scans to quickly stratify patient risk and guide urgent treatment decisions.
View Rapid RV/LV →Choose ElucidVivo A.3 if…
Choose ElucidVivo A.3 if your focus is on detailed, quantitative analysis of arterial plaque composition to stratify patients with atherosclerosis and optimize long-term treatment. This system is best suited for cardiology and vascular surgery departments needing in-depth insights into plaque stability, including lipid-rich necrotic core and calcifications, to inform personalized management strategies for chronic cardiovascular disease.
View ElucidVivo A.3 →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Rapid RV/LV | ElucidVivo A.3 |
|---|---|---|
| Pricing | Contact vendor for pricing information. | Unknown |
| Deployment | Unknown | Cloud and on-premise secure deployment. |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Rapid RV/LVRapid RV/LV emphasizes rapid results within minutes of a scan and offers triage and notification capabilities, streamlining workflow for acute pulmonary embolism assessment. Its integration into a broader platform with mobile and web apps further enhances ease of use and team communication. While ElucidVivo A.3 offers detailed visualizations, its specialized analysis might imply a slightly more involved user experience.
Clinical Value
ElucidVivo A.3ElucidVivo A.3 provides highly detailed, quantitative analysis of arterial plaque composition and stability, including Lipid-Rich Necrotic Core (LRNC) quantification and FFRct derivation, validated against histology. This offers a deeper, more predictive insight into atherosclerosis, demonstrating a 40% improvement in predictive accuracy for major adverse neurologic events compared to stenosis alone. While Rapid RV/LV is crucial for acute PE assessment, ElucidVivo A.3's novel biomarkers offer a more profound impact on long-term patient stratification and personalized treatment.
Pricing & Value
TieBoth Rapid RV/LV and ElucidVivo A.3 require direct contact with the vendor for pricing information. Without specific pricing models, licensing structures, or publicly available return on investment (ROI) studies for either tool, it is not possible to conduct a head-to-head comparison of their pricing and value.
Enterprise Readiness
Rapid RV/LVRapid RV/LV explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), along with flexible deployment options (on-premises or hybrid) and integration within a broader Rapid platform. While ElucidVivo A.3 integrates with PACS/EMR, its HIPAA compliance and BAA availability are implied rather than explicitly stated in the provided information, giving Tool A a stronger documented posture for enterprise deployment.
Innovation
ElucidVivo A.3ElucidVivo A.3 demonstrates a higher degree of innovation by providing novel, histology-validated quantitative analysis of arterial plaque composition and stability, including the quantification of Lipid-Rich Necrotic Core (LRNC) and derivation of fractional flow reserve (FFRct). This goes beyond automating existing measurements to offer new, predictive biomarkers for atherosclerosis. Rapid RV/LV, while valuable, primarily automates an established clinical measurement (RV/LV ratio) for speed and consistency.
Support & Docs
Rapid RV/LVRapidAI offers comprehensive 24/7/365 global customer support via email and phone, along with extensive online resources including expert guides, videos, and learning materials. In contrast, the provided information for ElucidVivo A.3 does not detail specific support hours, documentation, or educational resources, making Rapid RV/LV the clear winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Rapid RV/LV | ElucidVivo A.3 |
|---|---|---|
| Tool Name | Rapid RV/LV | ElucidVivo A.3 |
| Company | RapidAI (formerly iSchemaView) | Elucid Bioimaging |
| Primary Focus | Rapid assessment of pulmonary embolism severity by automatically measuring right and left ventricle ratios from CTPA scans. | Quantitative analysis of arterial plaque composition and stability from CT angiography to assist in atherosclerosis patient stratification and optimize treatment decisions. |
| Key Analytical Output | Automated measurement of right and left ventricle diameters, calculation of RV/LV ratio, annotated images showing ventricular measurements. | Quantitative analysis of arterial plaque (Lipid-Rich Necrotic Core (LRNC), matrix, calcifications), visualization of lesion-level plaque composition, 3D visualization of highlighted vessels, rotatable curved MPR vessel views and cross-sections, derives fractional flow reserve (FFRct). |
| Target Medical Condition | Pulmonary embolism severity | Atherosclerosis patient stratification |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Radiology, Vascular Surgery |
Videos
Demos, reviews, and walkthroughs featuring Rapid RV/LV and ElucidVivo A.3.